Skip to main content
SpringerLink
Log in

Current diagnosis and treatment of temporal arteritis

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Corticosteroid treatment should start directly after suspected diagnosis. The diagnosis should be confirmed within the next 5 days by histology or ultrasound. Clinical assessment includes auscultation of the axillary arteries in the search for large-vessel giant cell arteritis. Angiography, magnetic resonance angiography, positron emission tomography, or ultrasound can confirm the diagnosis of large-vessel giant cell arteritis. The initial prednisolone dose is 40 to 70 mg/d. It should be reduced in weekly steps of 5 to 10 mg until 20 mg/d, and by 2.5 mg until 10 mg/d. Dose reduction is 1 mg/mo below 10 mg/d, depending on symptoms and erythrocyte sedimentation rate or C-reactive protein. Patients with ophthalmologic complications receive three to four daily infusions of 250 mg of methylprednisolone for 3 days. Low-dose aspirin reduces the risk of ophthalmologic and cardiovascular complications. The benefit of methotrexate as a corticosteroid-sparing agent is controversial. Corticosteroid treatment requires monitoring of glucose, blood and eye pressure, and adequate prevention of osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Smetana GW, Shmerling RH: Does this patient have temporal arteritis? JAMA 2002, 287:92–101.

    Article  PubMed  Google Scholar 

  2. Schmidt WA, Gromnica-Ihle E: What is the best approach to diagnose large-vessel vasculitis? Best Pract Res Clin Rheumatol 2005, 19:223–242.

    Article  PubMed  Google Scholar 

  3. Danesh-Meyer H, Savino PJ, Gamble GG: Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005, 112:1098–1103.

    Article  PubMed  Google Scholar 

  4. Nuenninghoff DM, Hunder GG, Christianson TJ, et al.: Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum 2003, 48:3522–2531.

    Article  PubMed  Google Scholar 

  5. Hunder GG: Treatment of giant cell (temporal) arteritis. In UpToDate. Edited by Rose BD. Waltham, MA: 2005. http://www.uptodate.com.

  6. Zehr KJ, Mathur A, Orszulak TA, et al.: Surgical treatment of ascending aortic aneurysms in patients with giant cell aortitis. Ann Thorac Surg 2005, 19:1512–1517.

    Article  Google Scholar 

  7. Taylor-Gjevre R, Vo M, Shukla D, Resch L: Temporal artery biopsy for giant cell arteritis. J Rheumatol 2005, 32:1186–1188. The first of a couple of studies that show that a very long biopsy specimen does not improve the histologic detection of temporal arteritis.

    Google Scholar 

  8. Schmidt WA, Gromnica-Ihle E: Incidence of temporal arteritis in patients with polymyalgia rheumatica: a prospective study using colour Doppler ultrasonography of the temporal arteries. Rheumatology 2002, 41:46–52.

    Article  PubMed  CAS  Google Scholar 

  9. Schmidt WA, Kraft HE, Vorpahl K, et al.: Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med 1997, 337:1336–1342.

    Article  PubMed  CAS  Google Scholar 

  10. Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP: Test performance of ultrasonography for giant cell arteritis. Ann Intern Med 2005, 142:359–369. A meta-analysis of 23 studies with 2036 subjects on temporal artery ultrasonography. It shows that duplex ultrasonography has high sensitivity and specificity with regard to clinical and histology diagnosis of temporal arteritis.

    PubMed  Google Scholar 

  11. Schmidt WA, Gromnica-Ihle E: Duplex ultrasonography in temporal arteritis. Ann Intern Med 2003, 138:609; author reply 609–610.

    PubMed  Google Scholar 

  12. Bley TA, Wieben O, Uhl M, et al.: High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol 2005, 184:283–287. The first case-control study that evaluates MRI of the temporal arteritis in GCA. It shows a good correlation with clinical diagnosis and histology.

    PubMed  Google Scholar 

  13. Schmidt WA, Natusch A, Möller DE, et al.: Involvement of peripheral arteries in active giant cell arteritis: a study using color Doppler sonography. Clin Exp Rheumatol 2002, 20:309–318.

    PubMed  CAS  Google Scholar 

  14. Schmidt WA, Blockmans D: Use of ultrasonography and positron emission tomography in the diagnosis and assessment of large-vessel vasculitis. Curr Opin Rheumatol 2005, 17:9–15.

    Article  PubMed  Google Scholar 

  15. Meller J, Strutz F, Siefker U, et al.: Early diagnosis and follow-up of aortitis with [(18)F]FDG PET and MRI. Eur J Nucl Med Mol Imaging 2003, 30:730–736.

    Article  PubMed  CAS  Google Scholar 

  16. Younge BR, Cook BE Jr, Bartley B, et al.: Initiation of glucocorticoid therapy: before and after temporal artery biopsy. Mayo Clin Proc 2004, 79:483–491.

    Article  PubMed  Google Scholar 

  17. Chan CC, Paine M, O’Day J: Steroid management in giant cell arteritis. Br J Ophthalmol 2001, 85:1061–1064. Retrospectively compared high-dose intravenous corticosteroid treatment to lower doses of oral corticosteroid treatment. Intravenous medication was more effective in restoring visual function than oral medication.

    Article  PubMed  CAS  Google Scholar 

  18. Foroozan R, Deramo VA, Buono LM, et al.: Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology 2003, 110:539–542.

    Article  PubMed  Google Scholar 

  19. Jover JA, Hernandez-Garcia C, Morado IC, et al.: Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:106–114.

    PubMed  CAS  Google Scholar 

  20. Spiera RF, Mitnick HJ, Kupersmith M, et al.: A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001, 19:495–501.

    PubMed  CAS  Google Scholar 

  21. Hoffman GS, Cid MC, Hellmann DB, et al.: A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002, 46:1309–1318.

    Article  PubMed  CAS  Google Scholar 

  22. Hoffman GS, Cid MC, Weyand CM, et al.: Phase II study of the safety and efficacy of infliximab in giant cell arteritis (GCA): 22 week interim analysis. Arthritis Rheum 2005, 52(suppl):S271.

    Google Scholar 

  23. Salvarani C, Manzini C, Paolazzi G, et al.: Infliximab in the treatment of polymyalgia rheumatica: a doubleblind, randomized, placebo-controlled study. Arthritis Rheum 2005, 52(suppl):S676-S677.

    Google Scholar 

  24. Bhatia A, Ell PJ, Edwards JC: Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 2005, 64:1099–1100.

    Article  PubMed  CAS  Google Scholar 

  25. Nesher G, Berkun Y, Mates M, et al.: Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004, 50:1332–1337. Shows that patients who received 100 mg of aspirin before and at diagnosis of temporal arteritis had less ophthalmologic and cerebrovascular ischemic complications. Furthermore, patients who received aspirin in the first 3 months of their disease had less complications.

    Article  PubMed  CAS  Google Scholar 

  26. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis [no authors listed]. Arthritis Rheum 2001, 44:1496-1503.

  27. Ray JG, Mamdani MM, Geerts WH: Giant cell arteritis and cardiovascular disease in older adults. Heart 2005, 91:324–328. This population-based retrospective cohort study from Ontario, Canada, found a ratio for cardiovascular disease of 1.6 in patients with GCA versus patients with osteoarthritis, and 2.1 in patients with GCA versus control subjects who had neither GCA nor osteoarthritis.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Center for Rheumatology Berlin-Buch, Karower Str. 11, 13125, Berlin, Germany

    Wolfgang A. Schmidt MD

Authors
  1. Wolfgang A. Schmidt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schmidt, W.A. Current diagnosis and treatment of temporal arteritis. Curr Treat Options Cardio Med 8, 145–151 (2006). https://doi.org/10.1007/s11936-006-0007-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-006-0007-9

Keywords

Search

Navigation